FDA grants Orphan Drug Designation to axatilimab for treatment of patients with chronic graft versus host disease

This investigational monoclonal antibody that targets colony stimulating factor-1 receptor, has shown deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents, and is currently being evaluated in Phase 2 AGAVE-201 trial.

Biospace Inc.